Thumbs Up/Thumbs Down: The FDA damaged itself badly with the Sarepta OK
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Califf’s decision to bow to Janet Woodcock on Sarepta hurts the entire biotech industry.
Janet Woodcock’s decision to override the caustic internal criticism of Sarepta’s weak and at times misleading case for its Duchenne drug eteplirsen has damaged the FDA in ways that will leave a mark for years to come. Overruling her colleagues – including senior FDA officials — to provide an accelerated approval this week for this application sends a clear message to biotech: If you can muster enough public support for a campaign – which includes an erroneous study for bait — you should proceed full steam ahead. To his credit, FDA commissioner Robert Califf posted his own review of the case as well as the heated objections of two top regulators, including the current acting chief scientist. Not to his credit, Califf chose to stand down in “deference” to Woodcock’s intransigence, but not before chiding Sarepta for promoting a study that raised false hopes in the patient community, which swallowed it all hook, line and sinker. He was also none too happy that Sarepta stayed focused on its lobbying campaign rather than the clinical work that needed to be done. I sincerely hope that eteplirsen does everything that advocates devoutly believe it does, without presenting the dangers cited for a “scientifically elegant placebo.” And let’s hope patients aren’t left to cover any of the $300,000 annual cost. Payers, and ultimately society, can and should do that now. And what happens next? Does the FDA now slap back the next company to use similar tactics, to try and reestablish old boundaries? Or does it lower its standards permanently, encouraging more large demonstrations and dodgy data to back weak applications? That’s a position the FDA should never have been put in. And that is on Janet Woodcock and Robert Califf.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.